EARLY DETECTORS OF DISEASE
CNA Diagnostics Inc.
CNAD
FORWARD-LOOKING INFORMATION
This presentation contains "forward-looking information", which is disclosureregarding possible events, conditions or financial performance that is based onassumptions about future economic conditions and courses of action. In particular,the forward-looking information in this presentation includes: statements regardingtiming and outcomes of research, development, and commercialization activities,financing activities, protection of intellectual property, market share and growth.Actual results may vary from the forward- looking information in this presentation.Material risk factors that could cause actual results to differ materially from theforward-looking information include: (i) CNAD’s ability to develop commerciallyviable products; (ii) CNAD’s ability to achieve profitability; (iii) CNAD’s ability toproduce and market its products; (iv) CNAD’s ability to obtain regulatory approvalof its products; (v) CNAD’s ability to protect its intellectual property; (vi) competitiveand alternative technologies; and (vii) CNAD’s ability to obtain financing to supportits operations. The material factors or assumptions that were used to develop theforward-looking information in this presentation include: our ability to achieveresearch and development objectives, timing of proposed commercialization plans,ability to protect intellectual property, ability to secure needed financing or ourability to develop sufficient margins in the business through development ofproposed technology or other means. CNAD's views regarding possible events,conditions or financial performance may change. However, CNAD does not intendto update the forward-looking information in this presentation, except as requiredby applicable securities legislation.
ABOUT CNAD
A new molecular diagnostics company
developing DNA biomarker collections
that enable "early accurate” diagnosis of
preclinical disease conditions.
Our “dedicated bioinformatics” discovery
pipeline and next generation sequencing
will change the way we confront and
diagnose disease.
Our goal is the well being of animals that
is inherently linked to the status of
human health.
GROWING PROBLEMS
The way we deal with animal health is now
becoming a serious problem to human health.
The use of clinical observation for diagnosis of
disease reduces treatment options.
Most human diseases (60%) and infections
(75%) originate from the livestock sector.
Researchers have found that 13 of 56 livestock
diseases and infections account for more than
2.2 million human deaths each year.
GROWING PROBLEMS
Antimicrobial resistance is branded by the CDC
as one of our most serious health threats, with
estimated costs of $100 trillion by 2050.
Each year 2 million people in the USA become
infected with bacteria that are resistant to
antibiotics increasing the infection rate at a faster
pace than can be controlled.
80% of the antibiotics sold in the USA are used
on livestock while China’s livestock industry will
consume 1/3 of the world’s available antibiotics.
OUR SOLUTIONS
Early and accurate diagnosis of chronic
disease and infections in animals and
humans needs to be implemented to
protect global communities and the
human food supply from diseases that are
detected too late by present diagnostic
methods.
The earlier the diagnosis of disease, the
more likely it can be cured or successfully
managed and treated, increasing food
production from healthy animals.
OUR SOLUTIONS
Early diagnosis of disease allows for managed
reduction in the use of antibiotics, stopping the
need for broad spectrum applications to food
producing animals not requiring treatment.
Provide the ability to create better vaccines and
drugs by determining their therapeutic effect on
disease and infections over specific time points
through the progress of the disease.
VALUE PROPOSITION Our diagnostic biomarker platform could
prevent substantial losses to livestock
producers, beginning with the U.S. Beef
and Dairy Industry, currently losing $10
billion per year.
Our Value:
Early pre-clinical diagnosis (BSE 10 mos.)
Accurate detection (Yes or No)
Low costs per test
Rapid results
High volume throughput
Onsite capable testing
Multiple disease analysis
GLOBAL IVD MARKET
2013 2014 2015 2016 2017 2018 2019 2020
Gro
wth
in B
illio
ns
Year
This market includes Immunoassay, Clinical
Chemistry, Molecular Diagnostics, and Hematology
The in vitro (IVD) diagnostics market is poised to
reach $75 Billion in annual revenue by 2020.
$75 bn
DNA DIAGNOSTIC MARKET
2013 2014 2015 2016 2017 2018 2019 2020
Gro
wth
in B
illio
ns
Year
As part of the Molecular Diagnostics Market,
DNA testing has extraordinary potential.
The DNA diagnostics market is expected to
reach $19 Billion by 2020.
$19 bn
Disease
Selection
& Samples
Sequencing &
Bioinformatics
Biomarker
Development
Clinical
Validation
OUR BUSINESS MODEL
Distributors
Biomarker Development & Commercialization
Royalty Licenses
Regulatory
Approvals
Regulatory
Approvals
Vete
rin
ary
Med
ical
Revenue
OUR MARKET POTENTIAL
TOTALS (millions) 244.6 243.9 81.8 (Beef) 97.6 (Dairy)
BEEF & DAIRY ONLY
FINANCIAL PROJECTIONS
Description
(000’s)
2017 2018 2019 2020
Revenues 4,213 40,704 80,241 120,913
Cost of Sales 1,453 10,259 17,654 23,040
Gross Profit 2,760 30,445 62,587 97,873
EBITDA (*2 Biomarkers - NA only)
- 163 25,305 57,594 92,521
One Test for BEEF & One Test for DAIRY
CANADA & USA
MILESTONES
Commercial Sales
Begin Two New Biomarkers for Beef & Dairy
Sign Exclusive Veterinary Distributors
Sub-License Medical Biomarkers
Completion of High Throughput Diagnostic Device
2017
2018
Two Biomarker Developments for Beef & Dairy
Validate Low Throughput Test Device and Begin High Throughput Diagnostic Device
Companion Animal, Breast Cancer & Sepsis Collaborations
Seeking $5 million Potential Grant Approvals
2016
IP Transfer from U of C
Acquire Disease Samples
Receive Order for 3 Million Tests
Grant Approval $382,705
2015
Begin Collaboration Partnerships
Appoint Industry Directors
Target Disease Samples
Grant Approval €658,000
2014
COMPETITORS
ANIMAL HUMAN
IDEXX ROCHE
ABAXIS QIAGEN
BIORAD
ZOETIS
THERMO FISHER
* Denotes (DNA preclinical based testing)
bioMERIEUX
ABBOTT
GRAIL BIO *
1 SOLUTIONS FOR INDUSTRY PROBLEMS
SCALABLE GLOBAL PRODUCTS
HIGH BARRIERS TO ENTRY
TRACTION WITH NEAR TERM REVENUE
CORPORATE HIGHLIGHTS
2
3
4
5 DRIVERS FROM INDUSTRY LEADERSHIP
CONTACT INFORMATION
CNA Diagnostics Inc.
610 – 1414 8th St. SW,
Calgary, AB T2R 1J6
Contact:
Greg McCartney - CEO
(604) 560-1239
Tim Uniacke - EVP
(403) 714-0888